# Pilot & Feasibility Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $105,008

## Abstract

ABSTRACT (Overall for Pilot and Feasibility Program)
The Pilot and Feasibility Program, directed by Dr. Verkman, is focused on the identification of CF targets, the
development of screening assays and screening paradigms, and the identification of drug candidates. Two
Pilot Project slots will be allocated for years 16–20. Each Pilot Project runs for a maximum of 2 years, with
second year funding requiring satisfactory progress and justification for continued funding. Pilot project
selection involves project recruitment, letters of intent, initial review by an Internal Advisory Committee, and
generally external review by our External Advisory Committee and ad hoc reviewers. Recent accomplishments
of the Pilot Program include manuscripts, patents, new grants, and potential out-licensing of CF drug
candidates. The proposed pilots for funding in year 16 focus on a potential new mutation-agonist CF target,
SLC26A9, and therapeutic development for a rare CF-causing CFTR mutation, C.3700A>G.

## Key facts

- **NIH application ID:** 10001910
- **Project number:** 2P30DK072517-16
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** ALAN S VERKMAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $105,008
- **Award type:** 2
- **Project period:** 2005-08-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001910

## Citation

> US National Institutes of Health, RePORTER application 10001910, Pilot & Feasibility Program (2P30DK072517-16). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10001910. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*